Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSCW) Change in Cash (2020 - 2025)

Historic Change in Cash for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to -$538357.0.

  • Ensysce Biosciences' Change in Cash fell 11730.85% to -$538357.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 million, marking a year-over-year decrease of 19223.43%. This contributed to the annual value of $2.4 million for FY2024, which is 21750.78% up from last year.
  • Per Ensysce Biosciences' latest filing, its Change in Cash stood at -$538357.0 for Q3 2025, which was down 11730.85% from -$840916.0 recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' Change in Cash registered a high of $7.7 million during Q2 2021, and its lowest value of -$4.7 million during Q2 2022.
  • Over the past 5 years, Ensysce Biosciences' median Change in Cash value was -$538357.0 (recorded in 2025), while the average stood at $77842.3.
  • As far as peak fluctuations go, Ensysce Biosciences' Change in Cash skyrocketed by 112214.09% in 2021, and later plummeted by 409505.19% in 2022.
  • Over the past 5 years, Ensysce Biosciences' Change in Cash (Quarter) stood at $5.4 million in 2021, then crashed by 125.01% to -$1.4 million in 2022, then skyrocketed by 74.86% to -$340777.0 in 2023, then tumbled by 91.19% to -$651515.0 in 2024, then rose by 17.37% to -$538357.0 in 2025.
  • Its Change in Cash was -$538357.0 in Q3 2025, compared to -$840916.0 in Q2 2025 and -$449586.0 in Q1 2025.